Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.

Takaya Yamashita,Naohito Fujishima,Masatomo Miura,Takenori Niioka,Maiko Abumiya,Yoshinori Shinohara,Kumi Ubukawa,Miho Nara,Masumi Fujishima,Yoshihiro Kameoka,Hiroyuki Tagawa,Makoto Hirokawa,Naoto Takahashi

Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.

2016

Takaya Yamashita
Naohito Fujishima
Masatomo Miura
Takenori Niioka
Maiko Abumiya
Yoshinori Shinohara
Kumi Ubukawa
Miho Nara
Masumi Fujishima
Yoshihiro Kameoka
Hiroyuki Tagawa
Makoto Hirokawa
Naoto Takahashi

Background Tacrolimus is metabolized by cytochrome P450 (CYP) 3A4 and 3A5. We investigated the influence of CYP3A5 polymorphism and concurrent use of azole antifungal agents (AZ) on the pharmacokinetics of a once-daily modified-release tacrolimus formulation (Tac-QD) in patients after hematopoietic stem cell transplantation (HSCT).

Keywords:

Acute kidney injury
Pharmacology
Cytochrome P450
Hematopoietic stem cell transplantation
Tacrolimus
Polymorphism (computer science)
CYP3A5
Cytochrome P-450 CYP3A
Pharmacokinetics
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations